TW200808804A - Mirtazapine for the treatment of neuropathic pain - Google Patents
Mirtazapine for the treatment of neuropathic pain Download PDFInfo
- Publication number
- TW200808804A TW200808804A TW096114463A TW96114463A TW200808804A TW 200808804 A TW200808804 A TW 200808804A TW 096114463 A TW096114463 A TW 096114463A TW 96114463 A TW96114463 A TW 96114463A TW 200808804 A TW200808804 A TW 200808804A
- Authority
- TW
- Taiwan
- Prior art keywords
- pain
- treatment
- neuropathic pain
- lohas
- mirtazapine
- Prior art date
Links
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 28
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 28
- 229960001785 mirtazapine Drugs 0.000 title description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 claims abstract 4
- 208000002193 Pain Diseases 0.000 claims description 37
- 230000036407 pain Effects 0.000 claims description 34
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000935 antidepressant agent Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229940005513 antidepressants Drugs 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 201000001119 neuropathy Diseases 0.000 description 6
- 230000007823 neuropathy Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000002981 neuropathic effect Effects 0.000 description 5
- 208000033808 peripheral neuropathy Diseases 0.000 description 5
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000001032 spinal nerve Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000551546 Minerva Species 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010043269 Tension headache Diseases 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- PBBXJBOFMIHTSC-UHFFFAOYSA-N 1,6-dioxecane-2,5,7,10-tetrone Chemical compound O=C1CCC(=O)OC(=O)CCC(=O)O1 PBBXJBOFMIHTSC-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000001151 non-parametric statistical test Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002517 zygapophyseal joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06114316 | 2006-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200808804A true TW200808804A (en) | 2008-02-16 |
Family
ID=37006417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096114463A TW200808804A (en) | 2006-05-22 | 2007-04-24 | Mirtazapine for the treatment of neuropathic pain |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2026814A2 (enExample) |
| JP (1) | JP2009537601A (enExample) |
| AR (1) | AR061046A1 (enExample) |
| CA (1) | CA2651607A1 (enExample) |
| MX (1) | MX2008014287A (enExample) |
| PE (1) | PE20080455A1 (enExample) |
| TW (1) | TW200808804A (enExample) |
| WO (1) | WO2007135123A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6452954B2 (ja) * | 2013-05-16 | 2019-01-16 | 国立大学法人千葉大学 | 癌転移抑制剤 |
| PL3261645T3 (pl) | 2015-02-27 | 2021-12-06 | Dechra Limited | Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211171B1 (en) * | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
| HUP0204050A3 (en) * | 2000-01-19 | 2004-09-28 | Akzo Nobel Nv | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
| US7074961B2 (en) * | 2000-09-26 | 2006-07-11 | The Brigham And Women's Hospital, Inc. | Antidepressants and their analogues as long-acting local anesthetics and analgesics |
| UA83666C2 (ru) * | 2003-07-10 | 2008-08-11 | Н.В. Органон | Способ получения энантиомерно чистого миртазапина |
| TW200538100A (en) * | 2004-04-21 | 2005-12-01 | Akzo Nobel Nv | Mirtazapine salts |
-
2007
- 2007-04-24 TW TW096114463A patent/TW200808804A/zh unknown
- 2007-05-18 PE PE2007000615A patent/PE20080455A1/es not_active Application Discontinuation
- 2007-05-21 CA CA002651607A patent/CA2651607A1/en not_active Abandoned
- 2007-05-21 AR ARP070102181A patent/AR061046A1/es unknown
- 2007-05-21 JP JP2009511495A patent/JP2009537601A/ja active Pending
- 2007-05-21 MX MX2008014287A patent/MX2008014287A/es not_active Application Discontinuation
- 2007-05-21 WO PCT/EP2007/054872 patent/WO2007135123A2/en not_active Ceased
- 2007-05-21 EP EP07729316A patent/EP2026814A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2026814A2 (en) | 2009-02-25 |
| WO2007135123A3 (en) | 2008-03-13 |
| JP2009537601A (ja) | 2009-10-29 |
| CA2651607A1 (en) | 2007-11-29 |
| WO2007135123A2 (en) | 2007-11-29 |
| MX2008014287A (es) | 2008-11-18 |
| AR061046A1 (es) | 2008-07-30 |
| PE20080455A1 (es) | 2008-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shipton | Tramadol—present and future | |
| Zink et al. | Benefit-risk assessment of ropivacaine in the management of postoperative pain | |
| Misiołek et al. | Postoperative pain management—2018 consensus statement of the section of regional anaesthesia and pain therapy of the polish society of anaesthesiology and intensive therapy, the polish society of regional anaesthesia and pain therapy, the polish association for the study of pain and the national consultant in anaesthesiology and intensive therapy | |
| Buckenmaier III et al. | Anaesthetic agents for advanced regional anaesthesia: a North American perspective | |
| Yazigi et al. | Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with intrathecal sufentanil-morphine | |
| CN102985085B (zh) | 治疗双相型障碍的方法 | |
| Wiles et al. | Local anaesthetics and adjuvants–future developments | |
| JP2010504926A (ja) | 痛みの治療のための混合されたＯＲＬ１／μ−アゴニスト | |
| RS56523B1 (sr) | Tapentadol za sprečavanje i lečenje depresije i anksioznosti | |
| US20110034565A1 (en) | Psycho-pharmaceuticals | |
| EP4512473A2 (en) | Methods of treating behavior alterations | |
| Kumar Batra et al. | Bupivacaine/ketamine is superior to intra-articu-lar ketamine analgesia following arthroscopic knee surgery | |
| ES2649492T3 (es) | (S)-pirlindol o sus sales farmacéuticamente aceptables para uso en medicina | |
| KR101971412B1 (ko) | 정맥 내 투여용 이부프로펜의 투여 | |
| ES2649491T3 (es) | (R)-pirlindol y sus sales farmacéuticamente aceptables para uso en medicina | |
| TW200808804A (en) | Mirtazapine for the treatment of neuropathic pain | |
| Mohammed et al. | Intrathecal versus intravenous dexmedetomidine in characteristics of bupivacaine spinal block in lower abdominal surgery | |
| Hung et al. | Cutaneous analgesia and systemic toxicity of carbetapentane and caramiphen in rats | |
| US20070270413A1 (en) | Mirtazapine for the treatment of neuropathic pain | |
| TWI356699B (en) | Agent for treating interstitial cystitis and agent | |
| Johnson | Treatment of acute pain in cats | |
| CN114080221B (zh) | 用于减轻疼痛的布洛芬与曲马多的组合 | |
| RU2416398C1 (ru) | Способ коррекции болевого синдрома при состоянии отмены опиоидов | |
| Kamath et al. | Comparison of Efficacy of Intrathecal Morphine 100µg and 200µg for Postoperative Pain Relief in Patients Undergoing Lower Abdominal and Lower Limb Surgeries | |
| JP2019509321A (ja) | 疼痛を処置するための組み合わせ |